Page 13 - Managing Science Editor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Managing science editor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Managing Science Editor Today - Breaking & Trending Today

#AANAM – Disease Severity, Job Loss High in Black RRMS Patients in US

#AANAM – Disease Severity, Job Loss High in Black RRMS Patients in US
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United States , Victor Rivera , University Of Lisbon , University Of Pittsburgh , Society Of America , American Academy Of Neurology , Research In Multiple Sclerosis , Biomedical Sciences , Baylor College Of Medicine , Multiple Sclerosis News Todayteam , Black Hispanics , Baylor College , American Academy , Clinical Characteristics , Patients With Multiple Sclerosis , North American Registry , Multiple Sclerosis , African American , Expanded Disability Status Scale , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் , வெற்றியாளர் ரிவேரா , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் ,

#AANAM – Kesimpta Prevents MS Worsening in Newly Diagnosed

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Kesimpta (ofatumumab) may now be prescribed through the National Health Service (NHS) of England and Wales as an at-home, self-administered treatment for people with relapsing-remitting multiple sclerosis (RRMS) who are either having relapses or have other evidence of MS activity.
A poster presentation at the AAN meeting, based on Phase 3 data in newly diagnosed patients, also showed it effective at preventing disability progression in the absence of a relapse in this group.
The National Institute for Health Care and Excellence (NICE) made the recommendation to include Kesimpta in the NHS, allowing RRMS patients to access it at low and fixed prices, following Kesimpta’s recent approval in the U.K. for relapsing forms of multiple sclerosis (MS). ....

United States , Long Beach , Ludwig Kappos , David Martin , University Of Lisbon , University Of Basel , Biomedical Sciences , Columbia University , National Health Service , University Hospital , National Institute For Health Care , American Academy Of Neurology , Scottish Medicines Consortium , Multiple Sclerosis News Todayteam , National Institute , Health Care , American Academy , Annual Meeting , Reduces Disability Progression Independent , Relapse Activity , Relapsing Multiple Sclerosis , Expanded Disability Status Scale , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் ,

#AANAM – Measuring Blood Proteins in SPMS Could Predict Disability

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the proteins neurofilament light chain, known as NfL, and glial fibrillary acidic protein, or GFAP, are associated with an increased risk of worsening disability, new research shows.
Measuring levels of certain proteins in the blood can provide important information about a person’s health. NfL is released into the blood when neurons or nerve cells are damaged or destroyed. As such, levels of NfL in the blood are indicative of injury in the nervous system. GFAP, meanwhile, is associated with the activity of star-shaped neural support cells called astrocytes, and also is a marker of nervous system injury. ....

United States , Ludwig Kappos , Jens Kuhle , Novarti Mayzent , University Of Lisbon , University Of Basel , University Hospital Basel , Biomedical Sciences , University Hospital , Society Of America , University Of Pittsburgh , American Academy Of Neurology , Multiple Sclerosis News Todayteam , American Academy , Neurofilament Light Chain , Disability Worsening , Expanded Disability Status Scale , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் , லுட்விக் கப்போஸ் , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , பல்கலைக்கழகம் ஆஃப் பேசல் , பல்கலைக்கழகம் மருத்துவமனை பேசல் ,

#AANAM – Blacks, Whites Respond Differently to B-cell Targeting MS Therapies

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests.
“While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to have more severe courses of MS,” llya Kister, MD, said in a press release. Kister, of the NYU Grossman School of Medicine in New York, is the study’s senior author and a fellow of the American Academy of Neurology. ....

New York , United States , Marta Figueiredo , Lucia Saidenberg , University Of Lisbon , Grossman School Of Medicine , American Academy Of Neurology Annual Meeting , American Academy Of Neurology , Biomedical Sciences , Nyu Ms Care Center , Multiple Sclerosis News Todayteam , African American , American Academy , Emerging Science Session , Neurology Annual Meeting , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , மார்த்தா பிகுேய்ரேதோ , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , மொத்த மனிதர் பள்ளி ஆஃப் மருந்து , அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் ஆண்டு சந்தித்தல் , அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் , உயிர் மருத்துவ அறிவியல் ,

Novartis' Kesimpta for Relapsing MS Approved in UK as At-home Therapy

4.6
(8)
Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease.
More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans.
This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland, Singapore, Australia, Japan, Argentina, the United Arab Emirates, Albania, and India.
The U.K.’s National Institute for Health Care and Excellence (NICE) and the Scottish Medicines Consortium now will decide whether to add Kesimpta to their respective National Health Service (NHS), which would allow patients to access treatments at low or no cost. NI ....

New York , United States , United Kingdom , United Arab Emirates , Columbia University , Sanofi Genzyme , David Martin , Owen Pearson , Chinmay Bhatt , University Of Lisbon , Department Of Microbiology Immunology , Biomedical Sciences , National Health Service , Uk National Institute For Health Care , Healthcare Products Regulatory Agency , Laboratory Of Doctor Davida Fidock , University Nova De Lisboa , Scottish Medicines Consortium , Health Care , Morriston Hospital , Cell Biology , Doctor David , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , புதியது யார்க் ,